Dr. Simeone on Impact of PARP Inhibitors on Pancreatic Cancer

Diane M. Simeone, MD, director, Pancreatic Cancer Center, NYU Langone Health’s Perlmutter Cancer Center, discusses the impact of PARP inhibitors on pancreatic cancer.

PARP inhibitors alone contributed to doubling the progression-free survival in patients with pancreatic cancer, explains Simeone. In the post-POLO trial era, research is investigating the impact of PARP inhibitors plus another agent.

In the nonmetastatic setting, does a patient’s BRCA status impact their adjuvant therapy? PARP inhibitors, according to Simeone, may eventually be used in a prevention setting for patients who have germline BRCA mutations, though that is still several years away from consideration.